Drug Database
Back to search

Poland· PL-100417636

Xifaxan

A rifaximin product containing rifaximinum, registered in Poland by Delfarma Sp. z o.o.. The same ATC class is registered in 14 of our 19 countries.

ATC A07AA11

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedXifaxanATCA07AA11REGISTER NO.PL-100417636PACKS LISTED5CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about rifaximinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Rifaximin is registered in 14 of 19 countries.

Countries holding a registration under ATC A07AA11 (rifaximin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search rifaximin products by name

Rifaximin · ATC A07AA11

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rifaximin costs, country by country.

Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Rifaximin · price per daily dose (0.6 g)

USD · FX 28 Sept 2026

  • CH Switzerland$7.02
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Rifaximinum
Manufacturer
Delfarma Sp. z o.o.
Country
Poland (PL)
ATC code
A07AA11
ATC class
Rifaximin
Defined daily dose
0.6 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 5

  • gtin
    05909991396862
  • gtin
    05909991396879
  • gtin
    05909991396886
  • gtin
    05909991396893
  • gtin
    05909991396909

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

88 interactions on record for rifaximin.

Graded by severity as the source publishes them — 63 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check rifaximin against other medicinesHow interaction checks work

Rifaximin · interactions on record

88 records

  • 63 moderate
  • 25 info

Most severe, free to view

  • RolapitantA04AD14moderate
  • Sodium picosulfateA06AB08moderate
  • EliglustatA16AX10moderate
  • LonafarnibA16AX20moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rifaximin in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rifaximin products

Authorised across Europe · EMA

The same active substance is authorised in 20 EEA countries. Names it is sold under:

  • Austria · Colidimin, Refero
  • Belgium · Targaxan, Tixteller
  • Czechia · Normix
  • Germany · Rifaxan, Tixteller
  • Denmark · Faxinorm, Xifaxan
  • Spain · Spiraxin, Tixtar
  • Finland · Targaxan, Xifaxan
  • France · Tixtar
  • United Kingdom (Northern Ireland) · Normicron, Rifaximin
  • Greece · Rifacol
  • Hungary · Normix, Refero
  • Ireland · Rifaximin Alfasigma, Targaxan
  • Italy · Flonorm, Normix
  • Luxembourg · Refero, Targaxan
  • Netherlands · Tixteller, Xifaxan
  • Norway · Xifaxan
  • Portugal · Refero, Xifaxan
  • Romania · Normix, Tixteller
  • Sweden · Xifaxan
  • Slovakia · Normix, Refero

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/00d1f1df-e69b-4ed3-807c-6c8d7c366fe1
GET /v1/drugs/00d1f1df-e69b-4ed3-807c-6c8d7c366fe1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "200 mg",
  "packaging": "05909991396862 ¦ Rp ¦ 131705\n12 tabl.\n05909991396879 ¦ Rp ¦ 131706\n14 tabl.\n05909991396886 ¦ Rp ¦ 131707\n24 tabl.\n05909991396893 ¦ Rp ¦ 131708\n28 tabl.\n05909991396909 ¦ Rp ¦ 131709\n42 tabl.",
  "substance": "Rifaximinum 200 mg",
  "common_name": "Rifaximinum",
  "pl_product_id": "100417636",
  "pozwolenie_nr": "96/19",
  "auth_procedure": "IR",
  "authorisation_validity": "2029-03-14"
}
API referenceMCP serverPlans

See everything about rifaximin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console